Propranolol HydrochlorideThird Party Manufacturing in India

Propranolol Hydrochloride is a non-cardioselective beta-adrenergic receptor antagonist that blocks the action of catecholamines such as adrenaline and noradrenaline at beta-1 and beta-2 receptors. By competitively inhibiting these receptors, propranolol reduces heart rate, decreases myocardial contractility, and lowers cardiac output, which collectively reduces the workload on the heart and decreases oxygen demand. The blockade of beta-1 receptors in the heart leads to negative chronotropic and inotropic effects, while beta-2 receptor blockade in bronchial and vascular smooth muscle can cause bronchoconstriction and peripheral vasoconstriction. Propranolol also suppresses renin release from the kidneys, contributing to its antihypertensive effect. Unlike cardioselective beta-blockers, propranolol affects both cardiac and pulmonary pathways, making it suitable for conditions where comprehensive beta-blockade is desired. The extended release formulation provides sustained therapeutic plasma concentrations over 24 hours, allowing once-daily dosing for consistent blood pressure control and angina prophylaxis.

Therapeutic Uses

Propranolol Hydrochloride is prescribed for the management of:

• Hypertension: Reduces elevated blood pressure through combined cardiac output reduction and renin suppression, lowering the risk of stroke and cardiovascular events.
• Angina Pectoris: Decreases myocardial oxygen demand by reducing heart rate and contractility, providing effective prophylaxis against anginal episodes.
• Cardiac Arrhythmias: Controls supraventricular and ventricular arrhythmias by slowing AV conduction and reducing automaticity of cardiac pacemaker cells.
• Migraine Prophylaxis: Reduces frequency and severity of migraine attacks through vascular and neurological beta-blockade mechanisms.
• Essential Tremor: Alleviates tremors by blocking peripheral beta-2 receptors on skeletal muscle.

Why Manufacturers Choose Propranolol Hydrochloride

Propranolol Hydrochloride is one of the most established beta-blockers in global pharmacopoeias, with decades of clinical use and a well-documented safety profile. Its extensive formulation flexibility allows manufacturing in multiple dosage forms including extended release capsules, making it a staple for contract pharmaceutical manufacturers. The consistent demand from both domestic and export markets, particularly for ER capsule formulations in 40mg, 60mg, and 80mg strengths, ensures reliable production volumes for third party manufacturing operations. Indian manufacturers benefit from well-established API supply chains and cost-efficient production processes, making Propranolol ER a preferred molecule for PCD franchise and WHO-GMP certified export orders.